Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $68.67 Average PT from Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been given an average recommendation of “Moderate Buy” by the eleven ratings firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $68.6667.

A number of equities research analysts recently weighed in on GPCR shares. Guggenheim lowered their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, August 7th. JMP Securities dropped their target price on Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 7th. Lifesci Capital raised Structure Therapeutics to a “strong-buy” rating in a report on Monday, September 8th. HC Wainwright dropped their price objective on Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Finally, Zacks Research downgraded shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 17th.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $32.84 on Wednesday. The company has a market cap of $1.89 billion, a P/E ratio of -26.92 and a beta of -1.63. Structure Therapeutics has a one year low of $13.22 and a one year high of $40.06. The business’s 50-day simple moving average is $26.33 and its 200 day simple moving average is $22.97.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.01). Analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Large investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC grew its position in shares of Structure Therapeutics by 3,326.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company’s stock valued at $949,000 after buying an additional 53,216 shares during the last quarter. Allianz Asset Management GmbH bought a new stake in shares of Structure Therapeutics in the 2nd quarter worth approximately $228,000. Exchange Traded Concepts LLC boosted its position in Structure Therapeutics by 58.6% during the 2nd quarter. Exchange Traded Concepts LLC now owns 61,732 shares of the company’s stock valued at $1,280,000 after purchasing an additional 22,809 shares during the period. Signaturefd LLC grew its stake in Structure Therapeutics by 6,550.0% during the 2nd quarter. Signaturefd LLC now owns 6,650 shares of the company’s stock worth $138,000 after buying an additional 6,550 shares during the last quarter. Finally, Trexquant Investment LP increased its position in Structure Therapeutics by 127.6% in the first quarter. Trexquant Investment LP now owns 120,340 shares of the company’s stock worth $2,083,000 after buying an additional 67,464 shares during the period. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.